Effect of Catheter Ablation With vs Without Vein of Marshall Ethanol Infusion on Persistent Atrial Fibrillation | Atrial Fibrillation | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial FibrillationThe VENUS Randomized Clinical Trial

Educational Objective
To learn about procedures for the treatment of persistent atrial fibrillation (AF).
1 Credit CME
Key Points

Question  Does adding vein of Marshall ethanol infusion to the catheter ablation procedure reduce the recurrence of atrial fibrillation in patients with persistent atrial fibrillation?

Findings  In this randomized clinical trial that included 343 patients with persistent atrial fibrillation, catheter ablation with vein of Marshall ethanol infusion, compared with catheter ablation alone, resulted in freedom from atrial fibrillation or prolonged atrial tachycardia in 49% vs 38% at both 6 and 12 months, a difference that was statistically significant.

Meaning  In patients with persistent atrial fibrillation, treatment with combined catheter ablation and vein of Marshall ethanol infusion had better outcomes compared with catheter ablation alone.

Abstract

Importance  Catheter ablation of persistent atrial fibrillation (AF) has limited success. Procedural strategies beyond pulmonary vein isolation have failed to consistently improve results. The vein of Marshall contains innervation and AF triggers that can be ablated by retrograde ethanol infusion.

Objective  To determine whether vein of Marshall ethanol infusion could improve ablation results in persistent AF when added to catheter ablation.

Design, Setting, and Participants  The Vein of Marshall Ethanol for Untreated Persistent AF (VENUS) trial was an investigator-initiated, National Institutes of Health–funded, randomized, single-blinded trial conducted in 12 centers in the United States. Patients (N = 350) with persistent AF referred for first ablation were enrolled from October 2013 through June 2018. Follow-up concluded in June 2019.

Interventions  Patients were randomly assigned to catheter ablation alone (n = 158) or catheter ablation combined with vein of Marshall ethanol infusion (n = 185) in a 1:1.15 ratio to accommodate for 15% technical vein of Marshall ethanol infusion failures.

Main Outcomes and Measures  The primary outcome was freedom from AF or atrial tachycardia for longer than 30 seconds after a single procedure, without antiarrhythmic drugs, at both 6 and 12 months. Outcome assessment was blinded to randomization treatment. There were 12 secondary outcomes, including AF burden, freedom from AF after multiple procedures, perimitral block, and others.

Results  Of the 343 randomized patients (mean [SD] age, 66.5 [9.7] years; 261 men), 316 (92.1%) completed the trial. Vein of Marshall ethanol was successfully delivered in 155 of 185 patients. At 6 and 12 months, the proportion of patients with freedom from AF/atrial tachycardia after a single procedure was 49.2% (91/185) in the catheter ablation combined with vein of Marshall ethanol infusion group compared with 38% (60/158) in the catheter ablation alone group (difference, 11.2% [95% CI, 0.8%-21.7%]; P = .04). Of the 12 secondary outcomes, 9 were not significantly different, but AF burden (zero burden in 78.3% vs 67.9%; difference, 10.4% [95% CI, 2.9%-17.9%]; P = .01), freedom from AF after multiple procedures (65.2% vs 53.8%; difference, 11.4% [95% CI, 0.6%-22.2%]; P = .04), and success achieving perimitral block (80.6% vs 51.3%; difference, 29.3% [95% CI, 19.3%-39.3%]; P < .001) were significantly improved in vein of Marshall–treated patients. Adverse events were similar between groups.

Conclusions and Relevance  Among patients with persistent AF, addition of vein of Marshall ethanol infusion to catheter ablation, compared with catheter ablation alone, increased the likelihood of remaining free of AF or atrial tachycardia at 6 and 12 months. Further research is needed to assess longer-term efficacy.

Trial Registration  ClinicalTrials.gov Identifier: NCT01898221

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: Miguel Valderrábano, MD, Division of Cardiac Electrophysiology, Department of Cardiology, Houston Methodist Hospital, 6550 Fannin St, Ste 1801, Houston, TX 77030 (mvalderrabano@houstonmethodist.org).

Accepted for Publication: August 10, 2020.

Author Contributions: Drs Valderrábano and Peterson had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Valderrábano, Peterson, Schurmann, Natale, Dave, Afshar, Morillo.

Acquisition, analysis, or interpretation of data: Valderrábano, Peterson, Swarup, Schurmann, Makkar, Doshi, DeLurgio, Athill, Ellenbogen, Koneru, Dave, Giorgberidze, Afshar, Guthrie, Bunge, Kleiman.

Drafting of the manuscript: Valderrábano, Peterson, Schurmann, Athill, Ellenbogen, Afshar, Guthrie.

Critical revision of the manuscript for important intellectual content: Peterson, Swarup, Schurmann, Makkar, Doshi, DeLurgio, Athill, Ellenbogen, Natale, Koneru, Dave, Giorgberidze, Bunge, Morillo, Kleiman.

Statistical analysis: Valderrábano, Peterson, Morillo.

Obtained funding: Valderrábano.

Administrative, technical, or material support: Valderrábano, Schurmann, Makkar, DeLurgio, Ellenbogen, Giorgberidze, Guthrie, Bunge.

Supervision: Valderrábano, Natale, Giorgberidze, Afshar, Bunge, Morillo.

Other—data collection and review: Swarup.

Conflict of Interest Disclosures: Dr Valderrábano reported serving as a consultant for Biosense Webster; a speaker for Boston Scientific; research support member for Circa Scientific; and consultant and speaker for Baylis Medical. Dr Swarup reported providing research and consulting services to Biosense Webster, Boston Scientific, and Abbott outside the submitted work. Dr Athill reported receiving grants and other funding from Methodist Hospital Research Institute during the conduct of the study and grants and personal fees from Boston Scientific and Abbott Laboratories; grants from Biosense Webster; and personal fees from Janssen Pharmaceutical and Zoll Medical outside the submitted work. Dr Natale reported receiving personal fees from Biosense Webster, Biotronik, Medtronic, Boston Scientific, and Abbott during the conduct of the study and outside the submitted work. Dr Dave reported serving as a consultant to Abbott outside the submitted work. Dr Bunge reported receiving grants from Houston Methodist Research Institute during the conduct of the study. Dr Morillo reported receiving personal fees from Medtronic and serving as a member of the steering committee of the STAR AF trials for Abbott outside the submitted work. No other disclosures were reported.

Funding/Support: This study was funded by grant R01HL115003 from the National Institutes of Health/National Heart, Lung, and Blood Institute. Additional support came from Charles Burnett III and Lois and Carl Davis Centennial Chair endowments (Dr Valderrábano) and Houston Methodist Research Institute.

Role of the Funder/Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data Sharing Statement: See Supplement 3.

References
1.
Calkins  H , Hindricks  G , Cappato  R ,  et al.  2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.   Heart Rhythm. 2017;14(10):e275-e444. doi:10.1016/j.hrthm.2017.05.012PubMedGoogle Scholar
2.
Haïssaguerre  M , Jaïs  P , Shah  DC ,  et al.  Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins.   N Engl J Med. 1998;339(10):659-666. doi:10.1056/NEJM199809033391003PubMedGoogle Scholar
3.
Dixit  S , Marchlinski  FE , Lin  D ,  et al.  Randomized ablation strategies for the treatment of persistent atrial fibrillation: RASTA study.   Circ Arrhythm Electrophysiol. 2012;5(2):287-294. doi:10.1161/CIRCEP.111.966226PubMedGoogle Scholar
4.
Verma  A , Jiang  CY , Betts  TR ,  et al; STAR AF II Investigators.  Approaches to catheter ablation for persistent atrial fibrillation.   N Engl J Med. 2015;372(19):1812-1822. doi:10.1056/NEJMoa1408288PubMedGoogle Scholar
5.
Lee  SH , Tai  CT , Hsieh  MH ,  et al.  Predictors of non-pulmonary vein ectopic beats initiating paroxysmal atrial fibrillation: implication for catheter ablation.   J Am Coll Cardiol. 2005;46(6):1054-1059. doi:10.1016/j.jacc.2005.06.016PubMedGoogle Scholar
6.
Ulphani  JS , Arora  R , Cain  JH ,  et al.  The ligament of Marshall as a parasympathetic conduit.   Am J Physiol Heart Circ Physiol. 2007;293(3):H1629-H1635. doi:10.1152/ajpheart.00139.2007PubMedGoogle Scholar
7.
Kim  DT , Lai  AC , Hwang  C ,  et al.  The ligament of Marshall: a structural analysis in human hearts with implications for atrial arrhythmias.   J Am Coll Cardiol. 2000;36(4):1324-1327. doi:10.1016/S0735-1097(00)00819-6PubMedGoogle Scholar
8.
Kamanu  S , Tan  AY , Peter  CT , Hwang  C , Chen  PS .  Vein of Marshall activity during sustained atrial fibrillation.   J Cardiovasc Electrophysiol. 2006;17(8):839-846. doi:10.1111/j.1540-8167.2006.00516.xPubMedGoogle Scholar
9.
Báez-Escudero  JL , Morales  PF , Dave  AS ,  et al.  Ethanol infusion in the vein of Marshall facilitates mitral isthmus ablation.   Heart Rhythm. 2012;9(8):1207-1215. doi:10.1016/j.hrthm.2012.03.008PubMedGoogle Scholar
10.
Valderrábano  M , Chen  HR , Sidhu  J , Rao  L , Ling  Y , Khoury  DS .  Retrograde ethanol infusion in the vein of Marshall: regional left atrial ablation, vagal denervation and feasibility in humans.   Circ Arrhythm Electrophysiol. 2009;2(1):50-56. doi:10.1161/CIRCEP.108.818427PubMedGoogle Scholar
11.
Dave  AS , Báez-Escudero  JL , Sasaridis  C , Hong  TE , Rami  T , Valderrábano  M .  Role of the vein of Marshall in atrial fibrillation recurrences after catheter ablation: therapeutic effect of ethanol infusion.   J Cardiovasc Electrophysiol. 2012;23(6):583-591. doi:10.1111/j.1540-8167.2011.02268.xPubMedGoogle Scholar
12.
Báez-Escudero  JL , Keida  T , Dave  AS , Okishige  K , Valderrábano  M .  Ethanol infusion in the vein of Marshall leads to parasympathetic denervation of the human left atrium: implications for atrial fibrillation.   J Am Coll Cardiol. 2014;63(18):1892-1901. doi:10.1016/j.jacc.2014.01.032PubMedGoogle Scholar
13.
Pambrun  T , Denis  A , Duchateau  J ,  et al.  MARSHALL bundles elimination, pulmonary veins isolation and lines completion for anatomical ablation of persistent atrial fibrillation: MARSHALL-PLAN case series.   J Cardiovasc Electrophysiol. 2019;30(1):7-15. doi:10.1111/jce.13797PubMedGoogle Scholar
14.
Valderrábano  M , Peterson  LE , Bunge  R ,  et al.  Vein of Marshall ethanol infusion for persistent atrial fibrillation: VENUS and MARS clinical trial design.   Am Heart J. 2019;215:52-61. doi:10.1016/j.ahj.2019.04.022PubMedGoogle Scholar
15.
Valderrábano  M , Liu  X , Sasaridis  C , Sidhu  J , Little  S , Khoury  DS .  Ethanol infusion in the vein of Marshall: adjunctive effects during ablation of atrial fibrillation.   Heart Rhythm. 2009;6(11):1552-1558. doi:10.1016/j.hrthm.2009.07.036PubMedGoogle Scholar
16.
Tilz  RR , Rillig  A , Thum  AM ,  et al.  Catheter ablation of long-standing persistent atrial fibrillation: 5-year outcomes of the Hamburg Sequential Ablation Strategy.   J Am Coll Cardiol. 2012;60(19):1921-1929. doi:10.1016/j.jacc.2012.04.060PubMedGoogle Scholar
17.
Gillinov  AM , Gelijns  AC , Parides  MK ,  et al; CTSN Investigators.  Surgical ablation of atrial fibrillation during mitral-valve surgery.   N Engl J Med. 2015;372(15):1399-1409. doi:10.1056/NEJMoa1500528PubMedGoogle Scholar
18.
Vogler  J , Willems  S , Sultan  A ,  et al.  Pulmonary vein isolation versus defragmentation: the CHASE-AF clinical trial.   J Am Coll Cardiol. 2015;66(24):2743-2752. doi:10.1016/j.jacc.2015.09.088PubMedGoogle Scholar
19.
Fink  T , Schlüter  M , Heeger  CH ,  et al.  Stand-alone pulmonary vein isolation versus pulmonary vein isolation with additional substrate modification as index ablation procedures in patients with persistent and long-standing persistent atrial fibrillation: the randomized alster-lost-af trial (ablation at St G0 rg Hospital for long-standing persistent atrial fibrillation).   Circ Arrhythm Electrophysiol. 2017;10(7):e005114. doi:10.1161/CIRCEP.117.005114PubMedGoogle Scholar
20.
Kim  JS , Shin  SY , Na  JO ,  et al.  Does isolation of the left atrial posterior wall improve clinical outcomes after radiofrequency catheter ablation for persistent atrial fibrillation? a prospective randomized clinical trial.   Int J Cardiol. 2015;181:277-283. doi:10.1016/j.ijcard.2014.12.035PubMedGoogle Scholar
21.
Tamborero  D , Mont  L , Berruezo  A ,  et al.  Left atrial posterior wall isolation does not improve the outcome of circumferential pulmonary vein ablation for atrial fibrillation: a prospective randomized study.   Circ Arrhythm Electrophysiol. 2009;2(1):35-40. doi:10.1161/CIRCEP.108.797944PubMedGoogle Scholar
22.
Lee  JM , Shim  J , Park  J ,  et al; POBI-AF Investigators.  The electrical isolation of the left atrial posterior wall in catheter ablation of persistent atrial fibrillation.   JACC Clin Electrophysiol. 2019;5(11):1253-1261. doi:10.1016/j.jacep.2019.08.021PubMedGoogle Scholar
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close